If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Olumiant ® ▼ (baricitinib)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Olumiant Summary of Product Characteristics (SmPC)
Olumiant® ▼ (baricitinib): Laboratory Monitoring
Neutrophil, lymphocyte, hemoglobin, and hepatic transaminases levels should be assessed prior to initiation of baricitinib, and lipids should be assessed 12 weeks after initiation.
Laboratory
Monitoring with Baricitinib Treatment
For
information on laboratory monitoring with baricitinb treatment please
see Table 1.
Table
1. Laboratory measures and monitoring guidance1
Laboratory
Measure
Action
Monitoring
Guidance
Lipid
parameters
Patients
should be managed according to international clinical guidelines
for hyperlipidaemia
12
weeks after initiation of treatment and thereafter according to
international clinical guidelines for hyperlipidaemia
Absolute
Neutrophil Count (ANC)
Treatment
should be interrupted if ANC
<
1 x 109 cells/L
and may be restarted once ANC return above this value
Before
treatment initiation and thereafter according to routine patient
management
Absolute
Lymphocyte Count (ALC)
Treatment
should be interrupted if ALC
<
0.5 x 109 cells/L
and may be restarted once ALC return above this value
Haemoglobin
(Hb)
Treatment
should be interrupted if Hb
<
8 g/dL and may be restarted once Hb return above this value
Hepatic
transaminases
Treatment
should be temporarily interrupted if drug-induced liver injury is
suspected
Please
refer to section 4.4 of the Olumiant Summary of Product
Characteristics for further information on special warnings and
precautions for use with baricitinib.
References
1.
Olumiant [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Glossary
ALC
= absolute lymphocyte count
ANC
= absolute neutrophil count
BARI
= baricitinib
▼ This
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:November 13, 2020
Are you satisfied with this content?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com